Guo, Christina
Sharp, Adam
Gurel, Bora http://orcid.org/0000-0002-5018-8078
Crespo, Mateus http://orcid.org/0000-0003-4043-8296
Figueiredo, Ines
Jain, Suneil
Vogl, Ursula
Rekowski, Jan http://orcid.org/0000-0002-5207-3864
Rouhifard, Mahtab
Gallagher, Lewis http://orcid.org/0000-0003-2694-3157
Yuan, Wei
Carreira, Suzanne http://orcid.org/0000-0002-5077-5379
Chandran, Khobe
Paschalis, Alec
Colombo, Ilaria http://orcid.org/0000-0002-0602-8667
Stathis, Anastasios
Bertan, Claudia
Seed, George http://orcid.org/0000-0002-1105-1781
Goodall, Jane
Raynaud, Florence http://orcid.org/0000-0003-0957-6279
Ruddle, Ruth http://orcid.org/0000-0003-0025-8872
Swales, Karen E. http://orcid.org/0000-0002-6572-1293
Malia, Jason
Bogdan, Denisa http://orcid.org/0000-0002-3017-4832
Tiu, Crescens http://orcid.org/0000-0002-0515-6130
Caldwell, Reece
Aversa, Caterina
Ferreira, Ana
Neeb, Antje
Tunariu, Nina
Westaby, Daniel
Carmichael, Juliet
Fenor de la Maza, Maria Dolores
Yap, Christina http://orcid.org/0000-0002-6715-2514
Matthews, Ruth
Badham, Hannah
Prout, Toby
Turner, Alison
Parmar, Mona http://orcid.org/0000-0001-7818-4100
Tovey, Holly
Riisnaes, Ruth
Flohr, Penny
Gil, Jesus http://orcid.org/0000-0002-4303-6260
Waugh, David
Decordova, Shaun
Schlag, Anna
Calì, Bianca
Alimonti, Andrea http://orcid.org/0000-0002-9362-2313
de Bono, Johann S. http://orcid.org/0000-0002-2034-595X
Article History
Received: 23 May 2023
Accepted: 28 September 2023
First Online: 16 October 2023
Competing interests
: A. Sharp, B.G., M.C., I.F., J.R., M.R., L.G., W.Y., S.C., K.C., A.P., C.B., G.S., J. Goodall, F.R., R. Ruddle, K.E.S., J.M., D.B., C.T., A.N., N.T., D. Westaby, J.C., M.D.F., C.Y., R.M., H.B., T.P., A.T., M.P., H.T., R. Riisnaes, A.F., P.F., S.D., A. Schlag and J.S.d.B. are employees of The ICR, which has a commercial interest in abiraterone, PARP inhibition in DNA-repair-defective cancers and PI3K–AKT pathway inhibitors. C.G. was an employee of The ICR during the conduct of this work, as well as submission, review, and revision of the manuscript, and is now an employee of Roche-Genentech. A. Sharp has received travel support from Sanofi, Roche-Genentech and Nurix, and speaker honoraria from Astellas Pharma and Merck Sharp & Dohme; has served as an advisor to DE Shaw Research and CHARM Therapeutics; and has been the chief or principal investigator of industry-sponsored clinical trials. J.S.d.B. has served on advisory boards and received fees from companies including Amgen, AstraZeneca, Astellas, Bayer, Bioxcel Therapeutics, Boehringer Ingelheim, Cellcentric, Daiichi, Eisai, Genentech/Roche, Genmab, GSK, Harpoon, Janssen, Merck Serono, Merck Sharp & Dohme, Menarini/Silicon Biosystems, Orion, Pfizer, Qiagen, Sanofi Aventis, Sierra Oncology, Taiho, Terumo and Vertex Pharmaceuticals. J.S.d.B. receives funding or other support for his research work from Daiich Sankyo, AstraZeneca, Astellas, Bayer, Cellcentric, Daiichi, Roche-Genentech, Genmab, GSK, Janssen, Merck Serono, MSD, Menarini/Silicon Biosystems, Orion, Sanofi Aventis, Sierra Oncology, Taiho, Pfizer and Vertex. J.S.d.B. was named as an inventor, with no financial interest, on US patent 8,822,438. J.S.d.B. has been the chief or principal investigator of many industry-sponsored clinical trials. S.J. has served on advisory boards and received fees from companies including Accord, AstraZeneca, Astellas, Bayer, Boston Scientific, Janssen and Pfizer; and reports research funding from Boston Scientific for other research projects. I.C. reports speaker, consultancy or advisory role activities for GSK, AstraZeneca, Novartis and MSD; travel grants from Tesaro, GSK, AstraZeneca and Janssen; and research funding (to institution as the principal investigator) from MSD, Bayer, Incyte, AstraZeneca and Vivesto. U.V. reports an advisory role (institutional) to Janssen, Astellas, Merck, MSD, Pfizer, Roche, Bayer, BMS and Novartis AAA; travel support from Janssen, Merck and Ipsen; being part of the speaker bureau for (compensated, institutional) Janssen, Astellas, Pfizer, Roche, SAMO, BMS and Ipsen; and grant funding from Fond’Action. A. Stathis serves as a principal investigator and receives institutional funding for clinical trials sponsored by AstraZeneca, Bayer, Incyte, Roche, Abbvie, ADC Therapeutics, Amgen, Cellestia, Loxo Oncology, Merck MSD, Novartis, Pfizer, Philogen and Roche; received travel grants from AstraZeneca and Incyte; served on advisory boards for Janssen and Roche; provided expert testimony to Bayer and Eli Lilly. M.D.F. received travel funding from Astellas, AstraZeneca, Pfizer, Pierre Fabre, Roche, Bristol Meiers Squibb, Novartis, MSD, Janssen and Bayer, and personal fees from Janssen, Pierre Fabre and Roche (all funding and fees were outside the submitted work). J. Gil has acted as a consultant for Unity Biotechnology, Geras Bio, Myricx Pharma and Merck KGaA. Pfizer and Unity Biotechnology have financially supported research in J. Gil’s laboratory (unrelated to the work presented here). J. Gil owns equity in Geras Bio. J. Gil is a named inventor on MRC and Imperial College patents, both related to senolytic therapies (the patents are not related to the work presented here). A.A. has been the principal investigator of industry-sponsored clinical trials sponsored by Astellas Pharma Inc., AstraZeneca, Sun Pharma Global FZE; has received consulting fees from Debiopharm; and owns shares in Oncosence. B.C., D. Waugh., R.C. and C.A. do not have any competing interest to declare.